At a glance
ClinicalIndex Comparison RecordN/ACompleted· 120 enrolled
Drug / intervention
sodium zirconium cyclosilicate (SZC) +1 moredrug
Likely dose
sodium zirconium cyclosilicate (SZC) 5 gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Sodium Zirconium Cyclosilicate Versus Sodium Polystyrene Sulfonate for Treatment of Hyperkalemia in Hemodialysis Patients: A Randomized Clinical Trial
In Brief
A clinical study evaluating sodium zirconium cyclosilicate (SZC) and sodium polystyrene sulfonate for Hyperkalemia. Completed, enrolled 120 participants across 1 site.
Detailed Summary
This study aims to compare the effects of Sodium Zirconium Cyclosilicate versus Sodium Polystyrene Sulfonate for treatment of hyperkalemia in patients undergoing regular hemodialysis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperkalemia
CountriesEgypt
Collaborators--
Timeline
N/ACompletedFinished
202420252026
First PostedSep 2023
Enrollment StartJan 2024
Primary CompletionOct 2024
Study CompletionDec 2024
TodayJul 2026
First PostedSep 8, 2023
Enrollment StartJan 15, 2024
Primary CompletionOct 15, 2024
Study CompletionDec 15, 2024
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 2.8 years ago
Interventions
sodium zirconium cyclosilicate (SZC)drug
60 patients will receive sodium zirconium cyclosilicate (SZC) 5 g once daily on non-dialysis days (15 gm/week) for 8 weeks.
sodium polystyrene sulfonatedrug
60 patients will receive sodium polystyrene sulfonate 15 g once daily on non-dialysis days (45 gm/week) for 8 weeks.